TEVA has added another 14% over the past month to trade at $36.58, and the Street is now playing catch-up — with targets still running above the current price and the upgrade cycle showing no sign of stalling.
The analyst picture is the clearest signal this week. Barclays raised its target to $42 from $40 on August 12, maintaining its Overweight rating — the firm's second upward revision this year. That follows Piper Sandler's lift to $44 from $42 in late July, also after holding Overweight throughout. The consensus mean target now sits at $41.40, about 13% above the current price. Every recent move in the analyst file has been a raise, with no cuts or downgrades visible in the past several months. The bull case centres on ecopipam's potential in Tourette Syndrome treatment and Teva's neurology and immunology pipeline. Bears point to inventory timing issues, sluggish uptake on newer products, and a TL1A futility read not expected until the second half of the year. The earnings factor score ranks near the bottom on EPS surprise (3rd percentile), which is a quiet flag against the otherwise bullish analyst narrative.
Short interest has nudged lower from last week's note — down from roughly 35.6 million shares to about 35 million as of August 18, a small day-on-day dip of 0.8% — but the four-week trend remains upward, with the short count still running roughly 3.4% higher than a month ago. That rebuild, noted in last week's note, has continued without any meaningful signal of stress in the borrow market. Availability remains extraordinarily loose at 2,103% of current short interest — more than twenty shares available to lend for every one already borrowed. Cost to borrow is just 0.47%, essentially unchanged on the week. The ORTEX short score sits at 41, in the bottom half of the universe, consistent with a stock where bearish positioning is modest rather than extreme.
Options positioning adds little drama to the picture. The put/call ratio has ticked up very slightly to 0.37, barely half a standard deviation above its 20-day average of 0.36. That is close to the 52-week low of 0.34 and a long way from the year's high of 0.76 — call-side interest continues to dominate, and there is no sign of defensive hedging building in the options market.
The institutional holder list gives some texture to the ongoing bid. WCM Investment Management added 8.7 million shares in the most recent reported period, making it one of the more active builders among top holders. Capital Research added 3.7 million. BlackRock and State Street also increased positions. One notable trimmer is Lingotto Investment Management, which cut by around 7.6 million shares. On the insider side, the CMO sold roughly $892,000 of stock in early August — a modest amount relative to the company's size, and the net 90-day insider position is actually positive at just over 372,000 shares, reflecting award grants alongside sales.
The July 29 earnings print is worth keeping in mind as a recent marker. TEVA moved 11.8% higher on the day and held a 9.6% gain over the following five sessions — a strong post-earnings reaction that has contributed to the 14% monthly run. The next quarterly print is not scheduled until November 4, so the near-term conversation shifts to pipeline news flow around ecopipam and any further TL1A trial updates, which the bear case flags as the key swing factor for the second half.
What to watch: whether the analyst target-raise cycle continues into the low-$40s, and whether the steady rebuild in short interest accelerates or reverses as TEVA closes in on those consensus targets.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
